Sir—We read with interest the article by Beilke et al.[1] summarizing their findings of an
observational study of a group of HIV-infected patients, some of whom were coinfected with …

Abstract HIV-1 and HTLV-1 infect CD4+ T lymphocyte but little is known about the impact of
coinfection on patient's immune response. In this study we have evaluated the spontaneous …

Co‐infections with HIV‐1 and the human T leukemia virus types 1 and 2 (HTLV‐1, HTLV‐2)
occur frequently, particularly in large metropolitan areas where injection drug use is a …

Two distinct families of human retroviruses, the human immunodeficiency viruses (HIVs) and
human T‐lymphotropic viruses (HTLVs), cause significant infections worldwide. The viruses …

Human T-lymphotropic virus type I (HTLV-I) provirus load was examined in a cohort of a
population in Guinea-Bissau among whom human immunodeficiency virus (HIV) type 2 is …

The discovery of human T-lymphotropic virus type III/lymphadenopathy-associated virus
(HTLV-III/LAV) has opened a window to the understanding of the spectrum of the acquired …

Human T-lymphotropic virus type III (HTLV-III) is a recently discovered retrovirus with tropism
and cytotoxicity for the OKT4+ lymphocytes that are depleted in the acquired immune …

Human T-lymphotropic virus type I (HTLV-I) causes HTLV-I-associated myelopathy/tropical
spastic paraparesis and adult T cell leukemia in a small percentage of infected individuals …

According to the latest Department of Health and Human Services guidelines for the use of
antiretroviral therapy (ART) in HIV-1-infected persons, initiation of ART is recommended for …

5/25/95 12/6/95 this writing, the patient is continuing to receive secondary prophylaxis with
sulfadiazine and pyrimethamine for toxoplasmosis. We agree with Fantry et al. that the not …